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Abstract: As for the majority of antiepileptic drugs, encephalopathy, manifested by transient 
somnolence, mood and motor disorders, is a possible side-effect. To our knowledge, there is 
little information about gabapentin-induced coma. We report a third case of gabapentin-induced 
coma where magnetic resonance-spectrometry was performed in diagnosis assessment.
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Introduction
Gabapentin is a widely used antiepileptic drug. As for the majority of these drugs, 
encephalopathy, manifested by transient somnolence, mood and motor disorders, is a 
possible side-effect. However, to our knowledge, only two gabapentin-induced coma 
cases have been reported (Buttler et al 2003; Dogukan et al 2006). We report a third 
case of gabapentin-induced coma where magnetic resonance (MR)-spectrometry was 
performed to further assess diagnosis.
Case-report
A 65-year old woman, with a history of nontreated hypertension, was admitted in the 
neurosurgical intensive care unit after an aneurysmal subarachnoid hemorrhage. After 
an initial generalized tonic clonic seizure, the Glasgow coma scale was 15/15, without 
any motor deﬁ  cit. A diffuse subarachnoid hemorrhage without clot was observed on 
the initial computed tomography (CT) scan (Fisher scale at 2). The arteriography 
evidenced an aneurysm of the anterior communicating artery that was treated by 
coiling within the ﬁ  rst 6 hours after admission. A control CT performed after the 
procedure showed a dilation of the ventricles, thus an external ventricular drainage 
(EVD) system was inserted. The drainage line was linked to a pressure gauge in order 
to monitor the intracranial pressure. Because of the initial seizure, a preventive treat-
ment by gabapentin, 600 mg three times/day p.o. was introduced, and as part of our 
local guidelines: Intravenous nimodipine (2 mg/h), paracetamol (1 g every 6 hours) 
and oral omeprazole (40 mg per day).
Extubation was carried out at day 1 as the patient was conscious and had no motor 
deﬁ  cit. Several hours after extubation, she gradually became comatose. At this time, 
intracranial pressure, transcranial Doppler and PaCO2 were normal. She was intu-
bated, given ventilatory assistance and sedated by continuous infusion of sufentanil 
(10 μg/h) and propofol (70 mg/h). A new CT ruled out rebleeding or the occurrence 
of an ischemic complication and conﬁ  rmed the correct placement of EVD system. 
An aspect of moderate diffuse cerebral edema was observed despite a permanent low 
intracranial pressure.
Sedation was maintained over 72 hours, ie, day 4. During this period, sedatives 
were daily stopped for neurological evaluation. No improvement in consciousness Neuropsychiatric Disease and Treatment 2007:3(5) 696
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was observed. Despite the normality of plasmatic protein 
S100B (Weiss et al 2006) and transcranial Doppler, an arte-
riography was performed at day 8; it ruled out vasospasm. 
The electroencephalogram (EEG) performed at day 7 without 
sedation showed evidence of a reactive alternating coma 
and the presence of diffuse slow waves. At day 9, EEG 
slowed down, impoverished, with diminished reactivity 
and rare spike foci located on the anterior area, considered 
to be potentially epileptic. The diagnosis of seizure was 
proposed and gabapentin dosage was increased to 900 mg 
three times/day. A new EEG carried out at day 14 showed 
triphasic slow waves additionally to the previously described 
spike foci. Soon after, neurological degradation ensued; she 
became deeply comatose. A new EEG as well as a most 
detailed evaluation of the former recordings eventually 
drew aside the diagnosis of seizure. The constant presence 
of slow waves with triphasic tendency suggested metabolic 
encephalopathy. No medical cause was found as the different 
hepatic, endocrinal and metabolic assessments were normal. 
A drug-induced encephalopathy was evoked. All treatments 
(gabapentin, omeprazole, nimodipine and paracetamol) were 
stopped at day 16. Gabapentin was replaced by oxcarbazepine 
at a dose of 300 mg twice a day. A progressive improvement 
of the neurological status was observed, with recovery of 
consciousness at day 19 allowing weaning of mechanical 
ventilation. The control EEGs carried out at day 21 and 28 
showed the disappearance of the slow triphasic waves.
Magnetic resonance imaging (MRI) was performed 
at day 18 (48 hours after gabapentin cessation), day 34 
and day 58 including an axial ﬂ  uid attenuation inversion 
recovery (FLAIR) sequence, diffusion weighted imaging, 
single-voxel spectroscopy on the pons (TE = 135 ms, TR 
= 1500 ms) and multivoxel spectroscopy (chemical shift 
imaging) on the basal ganglia (TE = 135 ms, TR = 1500 
ms). Resonances of N-acetyl aspartate (NAA), creatine and 
choline on the thalami, the lenticular nuclei and the pons were 
integrated using dedicated software. Morphologic changes 
were limited to a few ischemic punctiform lesions on the 
left anterior cerebral artery territory. On spectroscopy, the 
NAA/choline ratios were markedly reduced on the thalami 
(normal value = 1.77 ± 0.28, n = 4 controls) and on the len-
ticular nuclei (normal value = 1.80 ± 0.52, n = 4 control). 
Subsequent examinations showed a progressive increase of 
these ratios back to normal levels at day 58 (Figure 1).
Figure 1 Time changes in NAA/choline ratio in different regions of interest on MRS analysis.
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The patient has been included in a ongoing study where 
a daily blood serum sample was frozen at –80 °C in the ﬁ  rst 
8-days. These samples were used to measure retrospectively 
the gabapentin concentration (high performance liquid chro-
matography, using a ﬂ  uorimetric method implying molecule 
derivatisation after extraction of plasma [Lough 1995]) and 
ammonemia (NH3 Ammoniac kit, Roche Molecular Bio-
chemicals; normal values between 20 and 80 mg/L). The 
mean value for gabapentin was 5.8 ± 2.4 mg/L with each 
daily value below the upper threshold of 10 mg/L. As shown 
on Figure 2, ammonemia raised from day 8.
Discussion
Coma has not been reported in the monograph of gabapentin 
as a potential side effect (Laboratories 1994). We propose 
that our patient had gabapentin-induced coma according 
to 4 levels of evidences: clinical worsening after dose was 
increased, appearance of triphasic waves suggestive of meta-
bolic encephalopathy on EEG, clinical and EEG improvement 
after gabapentin was stopped and ﬁ  nally MR-spectroscopy 
ﬁ  ndings that were similar to those described in valproic 
acid induced-encephalopathy. The time course of clinical 
events represents the ﬁ  rst evidence of this diagnosis. The 
ﬁ  rst neurological deterioration began after the introduction 
of gabapentin and the second worsening ensued the increase 
in gabapentin dose. The improvement of consciousness 
followed gabapentin discontinuation. The second evidence 
was EEG showing triphasic waves suggestive of metabolic 
encephalopathy. Triphasic waves were ﬁ  rst observed by 
Bickford and Butt in 1955 (Bickford and Butt 1955). These 
waves have been described in metabolic encephalopathy 
and drug-induced toxicity cases such as the one secondary 
to sodium valproate (Rehman and Zafar 2005). They have 
also been described in several other brain damage such as 
accidental anoxia, hepatotoxicity, renal failure, hyperos-
motic states and acute intoxications (Bahamon-Dussan et al 
1989; Karnaze and Bickford 1984). In our case, the absence 
of lesion on CT and diffusion or FLAIR MRI sequences 
ruled out the features other than metabolic or drug-induced 
encephalopathy. EEG expert reviewing drew aside the 
diagnosis of seizure. Other potential metabolic encepha-
lopathies were excluded since different hepatic, endocrinal 
and metabolic assessments were normal. Furthermore, the 
slow triphasic waves increased contemporary to increasing 
gabapentin dose and disappeared after gabapentin was 
stopped. The CT showed a diffuse cerebral edema but 
0
20
40
60
80
100
120
140
160
180
200
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9
a
m
m
o
n
e
m
i
a
 
(
m
g
/
L
)
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intracranial pressure was not increased. This morphological 
aspect, consistently observed in our patient, has also been 
already observed in patients with hepatic or toxic encepha-
lopathies (Bernthal et al 1987; Silver et al 1996; Messiwala 
and Loeser 2001). On MR-spectroscopy, a decrease in the 
NAA/choline ratio, assumed to assess neuronal tissue, was 
observed while the patient was in a deep comatose state. 
The NAA/choline ratio is classically normal in subarach-
noid hemorrhage normal appearing white and grey matter. 
These anomalies, contrasting with normal morphological 
sequences, have already been described in the valproic acid 
induced-encephalopathy, which brain toxicity is mediated 
by hyperammonemia (Ziyeh et al 2002; Hamer et al 2000). 
It seems unlikely that metabolic encephalopathy was due 
to ammonemia since clinical symptoms occurred at day 2, 
ie, ﬁ  ve days before the onset of ammonemia increase. This 
indicates that hyperammonemia could be the consequence of 
gabapentin toxicity rather than the cause of the coma itself. 
The normalization of the NAA/choline ratio after gabapentin 
discontinuation followed the course of clinical and EEG 
improvement and further argues for a direct relationship 
between the modiﬁ  cations observed on MR-spectrometry and 
the drug effect on consciousness as in the case of valproic 
acid induced-encephalopathy. Some limitations exist for the 
implication of gabapentin in our case. The patients had other 
treatments discontinued at the same time as gabapentin. They 
did not seem to be a potential causes for coma since they 
are well-known molecules with no reported cases of drug-
induced encephalopathy. Paracetamol can induce coma but 
through hepatic failure that was not present in our case. Two 
cases of overdose of gabapetine without serious side effects 
has been previously reported (Fischer et al 1994; Verma et al 
1999). The daily levels of gabapentin were below the upper 
threshold in our case. This discrepancy might be due to pre-
existing brain injury, ie, subarachnoid hemorrhage, which 
could trigger metabolic encephalopathy with lower levels 
of gabapentin. Particular susceptibility might exist in some 
patients as suggested in Buttler’s case (Buttler et al 2003).
Our case illustrates the usefulness of MR-spectroscopy 
in drug-related encephalopathy. A decrease NAA/Cr ratio 
contrasting with the absence of morphological lesions on 
MRI could suggest drug-related encephalopathy, especially 
if this is in accord with time course of drug intake and a 
suggestive EEG.
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